ARTICLE | Company News
FDA briefing docs rebuff MoxDuo IR
April 18, 2014 10:45 PM UTC
FDA's Bob Rappaport said the agency's review team has been "unable to conclude that there is a safety benefit" for MoxDuo IR morphine/oxycodone from QRxPharma Ltd. (ASX:QRX; OTCQX:QRXPY), which is und...